X

Trial Profile

Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; Biomarker; Therapeutic Use

Most Recent Events

12 Mar 2021 Planned End Date changed from 15 Jul 2023 to 1 Jun 2025.
22 Feb 2021 Planned primary completion date changed from 15 Jul 2023 to 1 Jul 2021.
22 Feb 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com